News

GlobalData on MSN2d
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...
Zacks.com on MSN2d
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...
The Pharma Letter3d
EC greenlight for Vertex’ Alyftrek
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...
Nasdaq2d
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
Vertex’s fifth CFTR modulator therapy, Alyftrek (vanza triple), is a next-in-class triple combination regimen that was approved by the FDA in December 2024 for treating people with CF aged six ...
EU approves Vertex's next-generation cystic fibrosis drug
Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...
Fierce Pharma2d
Regulatory tracker: Merck nabs FDA priority review in bid to soup up Winrevair’s label
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...